Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

Share Price is delayed by 15 minutes
Get Live Data
36.60    0.10 (0.27%)
Bid:
36.50
Ask:
36.70
Spread: 0.20 (0.548%)
Market Cap: £26.87m
CAR Live PriceLast checked at - London Stock Exchange

Intraday Carclo Share Chart

Interim Management Statement

22 Jan 2014 07:00

RNS Number : 2240Y
Carclo plc
22 January 2014
Β 

22 January 2014

Β 

Carclo plc

("Carclo" or "the group")

Β 

Interim Management Statement

Β 

Β 

The board announces that the group's operating businesses, as expected, are enjoying stronger trading in the second half of the financial year but that lower than previously expected sales at Conductive Inkjet Technology ("CIT") will reduce the forecast profitability of CIT and hence of the group in the second half.

Β 

At CIT, sales of coated film in the second half are set to be ahead of the first half sales number, but below the board's previously disclosed estimated range. This is due to a slower than anticipated ramp up in production on the programs which are using XSenseβ„’ touch sensors. CIT's partner, Atmel Corporation ("Atmel"), recently announced its first production rollout for the HP Omni 10β„’ from its Colorado manufacturing site and Atmel continues to supply XSenseβ„’ for this program. Further programs are expected to progressively come on stream through the first half of 2014, benefitting from the superior capabilities of XSenseβ„’ (including narrow bezel capability) versus competitive offerings.

Β 

The market for XSenseβ„’ and other metal mesh solutions is growing rapidly as adoption begins to gain traction at the expense of ITO touch sensor solutions in this $5 billion market. At the same time we have seen competition in the market increase for all touch solutions, which is causing pricing pressure; while we expect developments in the touch sensor market to become clearer during 2014, this is likely to reduce coated film revenues and margins versus our previous estimates. The product capabilities of XSenseβ„’ are strong and we remain confident that it can gain a significant market share in this rapidly growing market.

Β 

The group's Technical Plastics, LED Technologies and Precision Engineering businesses are all performing in line with the board's expectations.

Β 

Technical Plastics has been awarded several new programs during the year and further significant program awards are anticipated within the next few months as this business enters a growth phase.

Β 

Within the LED Technologies Division we have secured new supercar lighting programs and anticipate further awards early in the next financial year which will drive significant growth in this specialist design and manufacturing business. Sales within the division's LED Optics are also growing well.

Β 

Precision Engineering continues to perform well and has maintained its prior year performance.

Β 

Progress at Carclo Diagnostic Solutions is as anticipated and we are on track to deliver working product prior to our year end for the previously disclosed trial project for an Acute Kidney Injury marker with EKF Diagnostics Systems plc.

Β 

The group's balance sheet is strong and its funding remains secure. The board looks forward to sales and profits progression across the group in the coming financial year.

Β 

Β 

- ENDS -

Β 

Β 

Enquiries:

Carclo plc

01924 268040

Chris Malley, Chief Executive

Robert Brooksbank, Finance Director

Weber Shandwick Financial

020 7067 0700

Nick Oborne / Stephanie Badjonat

Β 

Β 

Notes to editors

Β 

Carclo plc is a technology group. It is a public company whose shares are quoted on the London Stock Exchange.

Β 

Carclo's strategy has been to develop new technologies and products to drive future growth. Its investment in CIT has led to the introduction of a new material for use in Capacitive Touch Screens. Further investment has been made in Carclo Diagnostic Solutions, where a novel Point-of-Care hardware platform has been developed.

Β 

Approximately three fifths of revenues are currently derived from the supply of fine tolerance, injection moulded plastic components, which are used in medical, optical and electronics products. This business, Carclo Technical Plastics, operates internationally in a fast growing and dynamic market underpinned by rapid technological development.

Β 

Approximately two fifths of revenues are derived from the supply of specialised precision LED based systems to the premium automotive industry, as well as key control systems for the aerospace industry.

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSPGUPCGUPCUCP
Date   Source Headline
12th Jul 201811:25 amBUSForm 8.3 - Carclo plc - Ordinary shares
12th Jul 201811:00 amRNSForm 8.3 - Carclo plc
11th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
11th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
10th Jul 20185:50 pmRNSForm 8.3 - [Carclo plc]
10th Jul 20185:27 pmRNSForm 8.3 - [Carclo plc]
10th Jul 20184:10 pmRNSForm 8.3 - [carclo plc]
10th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
10th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
10th Jul 20189:57 amBUSForm 8.3 - Carclo PLC
9th Jul 20183:55 pmRNSForm 8.3 - Carclo plc
9th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
9th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
9th Jul 201810:39 amRNSForm 8.3 - Carclo plc
6th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
6th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
5th Jul 201812:09 pmRNSForm 8 (OPD) - CONSORT MEDICAL PLC
5th Jul 201812:08 pmRNSForm 8 (OPD) - Carclo plc
5th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
4th Jul 20183:04 pmRNSHolding(s) in Company
4th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
4th Jul 201810:26 amRNSForm 8.3 - Carclo plc
3rd Jul 20184:22 pmRNSForm 8.3 - Carclo Plc
3rd Jul 20182:33 pmPRNForm 8.3 - Carclo plc
3rd Jul 20182:26 pmRNSForm 8.3 - [Carclo plc]
3rd Jul 20181:56 pmRNSForm 8.3 - Carclo Plc
3rd Jul 20181:49 pmRNSHolding(s) in Company
3rd Jul 20181:32 pmRNSForm 8.3 - Carclo plc
3rd Jul 20181:00 pmRNSForm 8.3 - Carclo plc
3rd Jul 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
3rd Jul 201811:36 amBUSForm 8.3 - Carclo plc - Ordinary shares
3rd Jul 201811:07 amRNSForm 8.3 - [Carclo plc]
2nd Jul 20181:07 pmRNSResponse to announcement from Consort Medical
2nd Jul 20187:00 amRNSNon-Binding Proposal for Carclo plc
28th Jun 20187:00 amRNSBoard changes
6th Jun 201810:27 amRNSHolding(s) in Company
5th Jun 20187:00 amRNSFinal Results
17th Apr 20187:00 amRNSDirectorate Change
9th Apr 20188:25 amRNSYear End Trading Update
26th Jan 20185:25 pmRNSDirector/PDMR Shareholding
24th Jan 201812:43 pmRNSDirector/PDMR Shareholding (Replacement)
24th Jan 201810:12 amRNSDirector/PDMR Shareholding
17th Jan 201811:27 amRNSHolding(s) in Company
16th Jan 201811:44 amRNSHolding(s) in Company
15th Jan 20187:00 amRNSTrading Update and Board Changes
12th Jan 20182:55 pmRNSHolding(s) in Company
12th Jan 20181:45 pmRNSHolding(s) in Company
10th Jan 20185:01 pmRNSHolding(s) in Company
28th Nov 20175:30 pmRNSHolding(s) in Company
14th Nov 20177:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.